Literature DB >> 19519772

Interaction of catechol and non-catechol substrates with externally or internally facing dopamine transporters.

Ying-Jian Liang1, Juan Zhen, Nianhang Chen, Maarten E A Reith.   

Abstract

Our previous work suggested that collapsing the Na(+) gradient and membrane potential converts the dopamine (DA) transporter (DAT) to an inward-facing conformation with a different substrate binding profile. Here, DAT expressing human embryonic kidney 293 cells were permeabilized with digitonin, disrupting ion/voltage gradients and allowing passage of DAT substrates. The potency of p-tyramine and other non-catechols (d-amphetamine, beta-phenethylamine, MPP(+)) in inhibiting cocaine analog binding to DAT in digitonin-treated cells was markedly weakened to a level similar to that observed in cell-free membranes. In contrast, the potency of DA and another catechol, norepinephrine, was not significantly changed by the same treatment, whereas epinephrine showed only a modest reduction. These findings suggest that catechol substrates interact symmetrically with both sides of DAT and non-catechol substrates, favoring binding to outward-facing transporter. In the cocaine analog binding assay, the mutant W84L displayed enhanced intrinsic binding affinity for substrates in interacting with both outward- and inward-facing states; D313N showed wild-type-like symmetric binding; but D267L and E428Q showed an apparent improvement in the permeation pathway from the external face towards the substrate site. Thus, the structure of both substrate and transporter play a role in the sidedness and mode of interaction between them.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19519772      PMCID: PMC2696066          DOI: 10.1111/j.1471-4159.2009.06034.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  60 in total

1.  The role of conserved tryptophan and acidic residues in the human dopamine transporter as characterized by site-directed mutagenesis.

Authors:  N Chen; R A Vaughan; M E Reith
Journal:  J Neurochem       Date:  2001-05       Impact factor: 5.372

2.  Differential sensitivity to NaCl for inhibitors and substrates that recognize mutually exclusive binding sites on the neuronal transporter of dopamine in rat striatal membranes.

Authors:  A Tidjane Corera; J C Do-Régo; J Costentin; J J Bonnet
Journal:  Neurosci Res       Date:  2001-03       Impact factor: 3.304

3.  Differential effect of structural modification of human dopamine transporter on the inward and outward transport of dopamine.

Authors:  N Chen; J B Justice
Journal:  Brain Res Mol Brain Res       Date:  2000-02-22

4.  A missense mutation of the Na+ channel alpha II subunit gene Na(v)1.2 in a patient with febrile and afebrile seizures causes channel dysfunction.

Authors:  T Sugawara; Y Tsurubuchi; K L Agarwala; M Ito; G Fukuma; E Mazaki-Miyazaki; H Nagafuji; M Noda; K Imoto; K Wada; A Mitsudome; S Kaneko; M Montal; K Nagata; S Hirose; K Yamakawa
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-22       Impact factor: 11.205

5.  Dendrodendritic inhibition through reversal of dopamine transport.

Authors:  B H Falkenburger; K L Barstow; I M Mintz
Journal:  Science       Date:  2001-09-28       Impact factor: 47.728

6.  Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin.

Authors:  R B Rothman; M H Baumann; C M Dersch; D V Romero; K C Rice; F I Carroll; J S Partilla
Journal:  Synapse       Date:  2001-01       Impact factor: 2.562

Review 7.  The use of permeabilized cells to assay protein phosphorylation and catecholamine release.

Authors:  C A Gonçalves; C Gottfried; P R Dunkley
Journal:  Neurochem Res       Date:  2000-06       Impact factor: 3.996

Review 8.  Hypoxia and persistent sodium current.

Authors:  Anna K M Hammarström; Peter W Gage
Journal:  Eur Biophys J       Date:  2002-05-29       Impact factor: 1.733

9.  [3H]WIN 35,428 ([3H]CFT) binds to multiple charge-states of the solubilized dopamine transporter in primate striatum.

Authors:  L M Gracz; B K Madras
Journal:  J Pharmacol Exp Ther       Date:  1995-06       Impact factor: 4.030

10.  Cationic interactions at the human dopamine transporter reveal binding conformations for dopamine distinguishable from those for the cocaine analog 2 alpha-carbomethoxy-3 alpha-(4-fluorophenyl)tropane.

Authors:  Nianhang Chen; LingLing Sun; Maarten E A Reith
Journal:  J Neurochem       Date:  2002-06       Impact factor: 5.372

View more
  15 in total

1.  Susceptibility to traumatic stress sensitizes the dopaminergic response to cocaine and increases motivation for cocaine.

Authors:  Zachary D Brodnik; Emily M Black; Meagan J Clark; Kristen N Kornsey; Nathaniel W Snyder; Rodrigo A España
Journal:  Neuropharmacology       Date:  2017-08-01       Impact factor: 5.250

2.  An N-terminal threonine mutation produces an efflux-favorable, sodium-primed conformation of the human dopamine transporter.

Authors:  Rheaclare Fraser; Yongyue Chen; Bipasha Guptaroy; Kathryn D Luderman; Stephanie L Stokes; Asim Beg; Louis J DeFelice; Margaret E Gnegy
Journal:  Mol Pharmacol       Date:  2014-04-21       Impact factor: 4.436

3.  Hypocretin receptor 1 blockade produces bimodal modulation of cocaine-associated mesolimbic dopamine signaling.

Authors:  K A Levy; Z D Brodnik; J K Shaw; D A Perrey; Y Zhang; R A España
Journal:  Psychopharmacology (Berl)       Date:  2017-06-30       Impact factor: 4.530

4.  Dopamine transporter oligomerization: impact of combining protomers with differential cocaine analog binding affinities.

Authors:  Juan Zhen; Tamara Antonio; Shu-Yuan Cheng; Solav Ali; Kymry T Jones; Maarten E A Reith
Journal:  J Neurochem       Date:  2015-01-26       Impact factor: 5.372

5.  Functional properties of dopamine transporter oligomers after copper linking.

Authors:  Juan Zhen; Maarten E A Reith
Journal:  J Neurochem       Date:  2017-12-21       Impact factor: 5.372

6.  Membrane cholesterol modulates the outward facing conformation of the dopamine transporter and alters cocaine binding.

Authors:  Weimin C Hong; Susan G Amara
Journal:  J Biol Chem       Date:  2010-08-05       Impact factor: 5.157

7.  In vivo effects of amphetamine analogs reveal evidence for serotonergic inhibition of mesolimbic dopamine transmission in the rat.

Authors:  Michael H Baumann; Robert D Clark; William L Woolverton; Sunmee Wee; Bruce E Blough; Richard B Rothman
Journal:  J Pharmacol Exp Ther       Date:  2011-01-12       Impact factor: 4.030

8.  Site-directed mutations near transmembrane domain 1 alter conformation and function of norepinephrine and dopamine transporters.

Authors:  Bipasha Guptaroy; Rheaclare Fraser; Aalisha Desai; Minjia Zhang; Margaret E Gnegy
Journal:  Mol Pharmacol       Date:  2010-12-13       Impact factor: 4.436

9.  Cocaine-insensitive dopamine transporters with intact substrate transport produced by self-administration.

Authors:  Mark J Ferris; Yolanda Mateo; David C S Roberts; Sara R Jones
Journal:  Biol Psychiatry       Date:  2011-02-01       Impact factor: 13.382

10.  Importance of cholesterol in dopamine transporter function.

Authors:  Kymry T Jones; Juan Zhen; Maarten E A Reith
Journal:  J Neurochem       Date:  2012-10-11       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.